← Leaderboards
Ramasamy Sakthivel
Arteriocyte, Inc.
$826,003
Attributed
$2,478,008
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2008–11$2M$1.5M$1M$500K$0
'08
'09
'10
'11
Funding mix
By agency
NIH$2,478,008 · 1
By mechanism
R44$2,478,008 · 1
Top collaborators
- Christopher J Cooper3 shared
- Vincent J Pompili3 shared
Most similar at Arteriocyte, Inc.
Same institution · by research overlap
- Stephen Edward Fischer$399,563
- Hong Wang$219,995
- Meghan Samberg$224,994
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusAffectAdipose TissueCulture MediaAmputationAngiogenesisAllogenicAutologousAllograftingAbdominal FatBlood VesselsBone MarrowBone Marrow Stem CellCell CountAtherosclerosisCell LineCell PhysiologyCellsCell SurvivalBaseBiopsyClinically RelevantClinical TrialsDiabetic
Grant awards (3)
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i$586,833
R44 · FY2011 · HL
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i$1,609,381
R44 · FY2010 · HL
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i$281,794
R44 · FY2008 · HL